Saffron Science

The eye searches land on the same trials.

If you came looking for saffron for eyes, or for eyesight, you deserve the same studies in ordinary words. People with mild to moderate macular degeneration took about 20 milligrams of saffron a day. Against a placebo, the eye chart moved 0.69 letters, less than one line, and the retinal recording answered a little sooner. The authors called it modest. Sight was not given back. The fuller reading lives on saffronvision.com.

The chart. Each row is one line, and one line is five letters. The careful trial moved the chart by 0.69 letters, less than one letter on a line like these. This sample is not that result.

A clear capsule filled with deep red saffron powder.

The capsule. The macular trials used 20 milligrams a day of saffron, by mouth. That is a study amount, not a pinch from the kitchen.

An eye chart and a capsule, set side by side so the two are easy to tell apart. The numbers stay in the sentences. This is not a bottle we sell.

What the studies have found

A small chart change, and a recording that looked a little better.

The careful trial and the later open extension are the same papers the vision room holds. Here they are in brief, so an eye search still gets the numbers. The changes are generally modest.

The placebo trial

Less than one letter, with the glasses that help you most.

One hundred adults over 50, with mild to moderate macular degeneration and vision better than 20/70 in at least one eye, took 20 milligrams a day. Three months on saffron, three months on a placebo, then they switched. Anyone already taking an AREDS supplement kept it. Best-corrected acuity improved by 0.69 letters. The retinal recording, the mfERG, answered 0.17 milliseconds sooner. In the people who stayed on AREDS, the chart moved 0.73 letters and the response density rose 2.8 percent. Side effects were not clearly different from placebo.

PubMed 30343354

A year on

The modest signal that remained was the recording.

A 12-month open extension stayed with 93 adults on the same 20 milligrams a day. There was no placebo. At a year the center of the retinal recording was stronger, and the timing did not clearly change. Best-corrected acuity was 1.6 letters worse. The small chart gain from the crossover did not continue. An earlier open follow-up of 29 people described a larger chart change against where each person started. That study had no placebo, and it is not the 0.69 letter result. Both are written out on the vision page.

PubMed 38485112 · PubMed 22852021 · The full reading

Limits that matter

A slightly clearer recording is not new eyesight.

If you are hoping for a clearer newspaper, or a face across the room, these papers are smaller than that hope. The groups were 100, 93, and 29 people. Some of the work had no placebo. A better electrical recording is not yet everyday sight, and larger independent repeats are still limited.

Searches for glaucoma, or for diabetic eye disease, are not answered here. These trials were about mild to moderate macular degeneration, or early disease in the smaller follow-up. They do not say saffron treats, cures, or replaces standard care for macular degeneration, or for any other eye condition. The American Academy of Ophthalmology has called the evidence very limited, and that note is older than the crossover. The vision page keeps the citation.

The limits, in full

Forms used in the research

About 20 milligrams a day, by mouth.

The eye studies used a measured oral amount of saffron, about 20 milligrams a day. That is a description of the research, not an amount to take. A kitchen pinch is food, and it is a different exposure. The summaries do not hand you a crocin percentage or a brand.

How the vision page says this · The compounds, on the hub

How to read a paper

The same questions, asked once.

Before a study reassures you, look for a randomized design, a placebo, the dose, the months, and whether the test was the letter chart or the mfERG. The vision room walks through those questions beside the numbers. The hub keeps the general habit of reading a saffron paper.

How the vision page reads a trial · How the hub reads a paper

A last word

Eyesight is a medical question.

Age-related macular degeneration is a medical condition. What you have read is a short description of published research. Your eyes can answer differently from the group. This page is not a substitute for the clinician who knows them, and it does not replace standard care.

Nothing here says saffron treats, cures, or replaces standard care for macular degeneration or for any other eye condition. Pregnancy is a reason to skip a supplement. If you already take a medicine or an AREDS supplement for your sight, talk with the person who prescribed it before you add saffron, and before you stop anything. The trials used 20 milligrams a day, by mouth. A large amount of raw threads is a different exposure, and these studies did not test it.

If the worry around your sight has turned toward harming yourself, please reach a person. In the United States you can call or text 988, or visit 988lifeline.org. You do not have to sit with that alone.

If a bottle is ever linked from this house, someone will have opened the Amazon or Walmart page first. A future affiliate program may earn a commission from that visit. None is connected today. There is no product on this page, and no price.